Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

← catalyst calendar

NCT06772623 · readout ≤ 468 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

252estimated

Sites

118

Countries

Australia, Belgium, China +12

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-03-06

actual

When the study began enrolling

Primary completion

Nov 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Nov 2027

estimated

The whole study's end, after follow-up

First posted

2025-01-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Non Small Cell Lung Carcinoma

Interventions

Drug: Telisotuzumab Adizutecan — also filed as ABBV-400
Drug: Budigalimab — also filed as ABBV-181
Drug: Pembrolizumab
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Cisplatin

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan

measured Up to Approximately 84 Days

Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)

measured Up to Approximately 33 Months

Number of Participants with Adverse Events (AE)s

measured Up to Approximately 33 Months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed